Clinical trial
A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen
NCT05769608 is registered in ClinicalTrials.gov with Mineralys Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen
- Lead sponsor
- Mineralys Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 13, 2023
- Completion date
- January 15, 2025
- Enrollment
- 285 (actual)
- Sites
- 104
Conditions
As the registry lists them; a condition with its own page is linked.